Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CREBBP
REST API REST API
Homo sapiens
CREBBP is differentially expressed in 294 experiments: 141 organism parts: cerebellum, bone marrow, ... (139 more);, 203 disease states: normal, glioblastoma, ... (201 more);, 105 cell types 358 cell lines 41 compound treatments and 77 other conditions.
Synonyms CBP, RTS, KAT3A, RSTS
Orthologs CREBBP (Gallus gallus)   crebbpb (Danio rerio)   ENSCING00000009030 (Ciona intestinalis)   CREBBP (3 of 3) (Danio rerio)   Crebbp (Rattus norvegicus)   ENSCING00000017171 (Ciona intestinalis)   Crebbp (Mus musculus)   CREBBP (Bos taurus)   crebbpa (Danio rerio)   BDF1 (Saccharomyces cerevisiae)   BDF2 (Saccharomyces cerevisiae)   crebbp (Xenopus laevis)   CREBBP (Canis familiaris)   nej (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term DNA binding, regulation of S phase, protein binding, histone acetyltransferase activity, regulation of transcription, DNA-dependent, cytoplasm, acetyltransferase activity, nuclear chromatin, cell proliferation, innate immune response, protein complex, transcription, DNA-dependent, metal ion binding, protein complex assembly, response to hypoxia, signal transducer activity, transcription factor binding, homeostatic process, histone acetyltransferase complex, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, transcription cofactor activity, nucleus, histone acetylation, germ-line stem cell maintenance, transcription factor complex, nuclear body, chromatin binding, transferase activity, SMAD binding, nucleoplasm, signal transduction, positive regulation of transcription, DNA-dependent, zinc ion binding, MyoD binding, peroxisome proliferator activated receptor binding, N-terminal peptidyl-lysine acetylation, gene expression, interspecies interaction between organisms, p53 binding, cellular lipid metabolic process, condensed chromosome outer kinetochore, sequence-specific DNA binding transcription factor activity
InterPro Term DUF902_CREBbp, Znf_TAZ, Bromodomain, Znf_ZZ, KIX, Nuc_rcpt_coact_CREBbp, Histone_H3-K56_AcTrfase_RTT109
UniProt Accession Q92793, B5A221, B5A219, B5A218, B5A215, B5A214, B5A216, B5A211, B5A210, B5A213, B5A212, B5A232, B5A233, B5A230, B5A231, B5A229, B5A228, B5A227, B5A226, B5A225, B5A224, B5A223, B5A222, B5A240, B5A241, B5A242, B5A243, B5A244, B5A235, B5A234, B5A237, B5A236, B5A239, B5A238, B5A252, B5A253, B5A250, B5A248, B5A246, Q4LE28, O60424, Q75MY6, E9PEX7
Gene-Disease Assocation RUBINSTEIN-TAYBI SYNDROME 1; RSTS1
Search EB-eye ENSG00000005339
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, E-MTAB-62, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
BT474
2
E-MEXP-440, E-MTAB-37
HL-60
1
2
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
MKN74
1
E-GEOD-15460
NA19204
1
E-GEOD-19480
CCRFCEM
1
E-MTAB-37
352 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-3920, E-GEOD-4219, E-GEOD-13909, ... (48 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
CD4+ T cell
1
3
E-GEOD-16190, E-AFMX-5, E-MTAB-24, E-MTAB-25
embryonic stem cell
2
E-GEOD-26672, E-MEXP-930
CD8+ T cell
2
E-AFMX-5, E-TABM-145
monocyte
2
3
E-GEOD-11755, E-GEOD-22373, E-MEXP-2019, E-GEOD-5099, E-GEOD-8286 ... (5 experiments)
adult choroid from 76 y.o. donor
1
E-GEOD-18811
99 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-GEOD-16363, ... (60 experiments)

Factor Value U/D Experiments
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
prostate carcinoma
2
E-MTAB-62, E-GEOD-96
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
control
2
E-GEOD-21912, E-GEOD-16363
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
197 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-TABM-782, ... (24 experiments)

Factor Value U/D Experiments
none
2
4
E-TABM-782, E-GEOD-20719, E-GEOD-412, E-GEOD-5824, E-GEOD-5099, ... (6 experiments)
placebo
2
E-MEXP-1335, E-MEXP-1327
4,5-dianilinophthalimide
2
1
E-GEOD-5258
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
rapamycin
1
E-GEOD-5824
arsenic oxide
1
E-GEOD-6907
35 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
62 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-22148, E-GEOD-21138, E-GEOD-19665, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (13 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-TABM-15, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, E-GEOD-2487, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.386 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM